Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk
In a late-stage trial, the once-daily pill met cardiovascular safety criteria and showed a lower risk of major events than placebo, Eli Lilly said.
7 Articles
7 Articles
Daily pill could offer alternative to insulin injections for diabetes patients at cardiovascular risk
New research presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy, Sept. 28–Oct. 2, and published in The Lancet shows that, for people with type 2 diabetes at increased cardiovascular risk, a daily orforglipron pill had cardiovascular safety comparable to daily insulin glargine injections while providing greater improvements in weight and blood sugar control. However, gastrointestinal (GI) adverse events were more common with orforglipron, leading to more treatment discontinuations. The study was sponsored by Eli Lilly, the manufacturer of orforglipron.
LoudounTimes.com
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study
In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine
The ESD 2026 in Milan was a framework for announcing the results of ACHIEVE-4, the largest and longest study conducted so far on orforglipron, non-peptide oral GLP-1. At 52 weeks it produced greater reduction of glycated haemoglobin and body weight compared to insulin glargine, with less hypoglycemia but more gastrointestinal adverse events. The post EASD 2026. About oral diabetes T2 Orforglipron confirms cardiovascular safety and exceeds insuli…
Coverage Details
Bias Distribution
- 83% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
